- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05798338
Characterization of Extracellular Vesicles in Breast Cancer Patients
Characterization of Extracellular Vesicles in Breast Cancer Patients' Plasma by Single Molecule Detection Array (SiMoA) Digital ELISA
Extracellular vesicles (EVs) are lipid bilayer-delimited particles, naturally released from cells and mediators of intercellular cross-talk. In breast cancer (BC), EVs seem to be involved in the tumor microenvironment's shaping, in cancer cells invasion and in the set-up of metastasis.
Clinical studies have provided initial evidence that these vesicles may have a prognostic and predictive value in breast cancer. Considering their ubiquitous presence in body fluids and their minimally invasive assessment through blood sampling, EVs could have a potential as liquid biopsy-derived biomarkers. Their quantification though is a complex task requiring complicated and time-consuming pre-analytical procedures of EVs isolation.
This protocol want to develop a new method for the detection of tumor-derived-EVs associated proteins, based on the use of Single Molecule Array (SiMoA), a digital ELISA technology able to detect and quantify extremely low concentrations of target proteins or particles.
The aim of this study is to evaluate how this new technology can allow the quantification of EVs plasma levels in patients affected by BC, providing useful diagnostic and prognostic information.
Study Overview
Detailed Description
This is a prospective, observational, monocentric and no profit study. The study involves the analysis of plasma from patients with breast cancer in order to quantify and characterize tumor-derived EVs at specific disease stages.
The enrollment of consecutive patients affected by BC referring to an EUSOMA-accredited Breast Unit is planned.
The patients will be divided into three pre-planned groups, as follows:
Population 1: patients diagnosed with early breast cancer patients (stage I-III) with indication to curative surgery.
Population 2: a control group made of sex- and age-matched healthy volunteers, not affected by cancer or chronic diseases.
Population 3: patients with metastatic breast cancer diagnosis. For each patient a blood sample will be collected and plasma will be isolated. A new SiMoA assay based on the use of anti-CD63 and anti-CD9 antibodies, two well known protein markers of EVs, will be used to capture and quantify EVs directly from plasma without requiring any prior sample processing.
The study will be conducted following the International Conference on Harmonization [ICH] Good Clinical Practice [GCP] guidelines. The Ethical Committee of ICS Maugeri authorized the study as protocol 2490/2020.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Fabio Corsi, Professor
- Phone Number: 0382592272
- Email: fabio.corsi@icsmaugeri.it
Study Contact Backup
- Name: SARA PAOLA ALBASINI, MsC
- Phone Number: 3497378405
- Email: sara.albasini@icsmaugeri.it
Study Locations
-
-
Lombardy
-
Pavia, Lombardy, Italy, 27100
- Recruiting
- Istituti Clinici Scientifici Maugeri SpA
-
Contact:
- Fabio Corsi, Professor
- Phone Number: 0382592272
- Email: fabio.corsi@icsmaugeri.it
-
Contact:
- Sara Albasini, MsC
- Phone Number: 3497378405
- Email: sara.albasini@icsmaugeri.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Breast cancer patients
Description
Inclusion Criteria:
- Signing of a specific informed consent for participation to the study
- Female sex
Population 1:
- Diagnosis of early breast cancer;
- Indication for surgery after multidisciplinary discussion.
Population 2:
- Patients having a negative mammography or breast ultrasound within 12 months from the study enrollment.
Population 3:
- Diagnosis of metastatic breast cancer confirmed by cytological/histological examination or by imaging;
- Indication to chemotherapy.
Exclusion Criteria:
Population 1:
- Presence of distant metastases
- Synchronous presence of a different tumor
- Indication to neoadjuvant chemotherapy
Population 2:
- Diagnosis of breast cancer
- Synchronous presence of a different tumor or chronic disease
Population 3:
- Patients who are unfit for systemic chemotherapy treatment
Study Plan
How is the study designed?
Design Details
- Observational Models: CASE_CONTROL
- Time Perspectives: PROSPECTIVE
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Early Breast Cancer patients
|
Analysis of plasma in order to quantify and characterize EVs |
|
Metastatic Breast Cancer patients
|
Analysis of plasma in order to quantify and characterize EVs |
|
Healthy patients
- Patients having a negative mammography or breast ultrasound within 12 months from the study enrollment. |
Analysis of plasma in order to quantify and characterize EVs |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
EVs levels in early BC
Time Frame: 36 months
|
Determination of plasma EVs levels in patients with EBC by SIMOA digital ELISA and evaluation of the difference of their concentration compared to healthy controls |
36 months
|
|
EVs levels in metastatic BC
Time Frame: 36 months
|
Determination of plasma EVs levels in patients with first diagnosis of metastatic BC by SIMOA digital ELISA and evaluation of the difference of their concentration compared to healthy controls |
36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
EVs levels after surgery
Time Frame: 36 months
|
Determination of plasma EVs levels in patients with early BC one month after surgery and comparison with pre-surgery EVs levels in order to evaluate any qualitative of quantitative modifications in circulating EVs |
36 months
|
|
EVs levels after chemotherapy treatment
Time Frame: 36 months
|
Determination of plasma EVs levels in patients with first diagnosis of metastatic BC after 4 months of systemic therapy and comparison with pre-therapy EV's plasma levels |
36 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2490
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.